Vanguard Group Inc's 13G/A Filing for Monte Rosa Therapeutics Inc

The Vanguard Group Inc filed an amended Schedule 13G/A with the SEC, disclosing its ownership of 2,988,953 shares of Monte Rosa Therapeutics Inc's common stock, representing 4.83% of the total shares outstanding. The filing indicates that Vanguard holds these shares on behalf of its clients, including investment companies and managed accounts. The shares are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The filing was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025.